Inhibition of IGF-IR in a range of tumour types has antiproliferative effects and synergises with other anticancer therapies, including cytotoxic chemotherapies (Benini et al, 2001; Cohen et al, 2005; Yin et al, 2005; Abe et al, 2006). This evidence concerns the gene IGF1R and neoplasm.